Top

Published in:

01-06-2011

Plasma levels of angiostatin and endostatin remain unchanged for the first 3 weeks after colorectal cancer surgery

Authors: H. M. C. Shantha Kumara, Samer T. Tohme, Xiaohong Yan, Abu Nasar, Anthony J. Senagore, Matthew F. Kalady, Neil Hyman, Ik Y. Kim, Richard L. Whelan

Published in: Surgical Endoscopy | Issue 6/2011

Abstract

Introduction

Angiostatin and endostatin are endogenous inhibitors of angiogenesis with anticancer effects. After minimally invasive colorectal resection (MICR), blood levels of the proangiogenic factors vascular endothelial growth factor (VEGF) and angiopoetin 2 (Ang-2) are elevated for 2–4 weeks. Also, postoperative human plasma from weeks 2 and 3 after MICR has been shown to stimulate endothelial cell proliferation and migration, which are critical to angiogenesis. This proangiogenic state may stimulate tumor growth early after MICR. Surgery’s impact on angiostatin and endostatin is unknown. This study’s purpose is to determine perioperative plasma levels of these two proteins in colorectal cancer (CRC) patients undergoing MICR.

Methods

Endostatin levels were assessed in 34 CRC patients and angiostatin levels in 30 CRC patients. Blood samples were taken preoperatively and on postoperative day (POD) 1 and 3 in all patients; in a subset, samples were taken between POD 7 and 20. The late samples were bundled into 7-day blocks (POD 7–13, POD 14–20) and considered as single time points. Angiostatin and endostatin plasma levels were determined via enzyme-linked immunosorbent assay (ELISA) in duplicate. Wilcoxon signed-rank test and Student’s t test were used to analyze endostatin and angiostatin data, respectively. Significance was set at P < 0.0125 (after Bonferroni correction).

Results

There was a significant decrease in median plasma endostatin levels on POD 1, which returned to the preoperative level by POD 3. There was no significant difference between pre- and postoperative plasma angiostatin levels.

Conclusions

MICR has a very transient impact on plasma levels of endostatin and no impact on angiostatin during the first 21 days following surgery. Thus, angiostatin and endostatin do not likely contribute to or inhibit the persistent proangiogenic changes noted after MICR.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59:225–249PubMedCrossRef

Bird NC, Mangnall D, Majeed AW (2006) Biology of colorectal liver metastases: a review. J Surg Oncol 94:68–80PubMedCrossRef

Allendorf JD, Bessler M, Horvath KD, Marvin MR, Laird DA, Whelan RL (1998) Increased tumor establishment and growth after open vs. laparoscopic bowel resection in mice. Surg Endosc 12:1035–1038PubMedCrossRef

Leather AJ, Gallegos NC, Kocjan G, Savage F, Smales CS, Hu W, Boulos PB, Northover JM, Phillips RK (1993) Detection and enumeration of circulating tumour cells in colorectal cancer. Br J Surg 80:777–780PubMedCrossRef

Shantha Kumara HMC, Feingold D, Kalady M, Dujovny N, Senagore A, Hyman N, Cekic V, Whelan RL (2009) Colorectal resection is associated with persistent proangiogenic plasma protein changes: postoperative plasma stimulates in vitro endothelial cell growth, migration, and invasion. Ann Surg 249(6):973–977PubMedCrossRef

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedCrossRef

Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65:3967–3979PubMedCrossRef

O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315–328PubMedCrossRef

O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285PubMedCrossRef

10.

O’Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689–692PubMedCrossRef

11.

Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R (2005) Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 102:2934–2939PubMedCrossRef

12.

Sun Y, Wang J, Liu Y, Song X, Zhang Y, Li K, Zhu Z, Zhou Q, You L, Yao C (2005) Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 23, No 16S (June 1 Supplement) 7138

13.

Sharma MR, Tuszynski GP, Sharma MC (2004) Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J Cell Biochem 91:398–409PubMedCrossRef

14.

Shichiri M, Hirata Y (2001) Antiangiogenic signals by endostatin. FASEB J 15:1044–1053PubMedCrossRef

15.

Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B, Ramchandran R, Pestell R, Sukhatme VP (2002) Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 277:16464–16469PubMedCrossRef

16.

Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L (2001) Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152:1247–1254PubMedCrossRef

17.

MacDonald NJ, Shivers WY, Narum DL, Plum SM, Wingard JN, Fuhrmann SR, Liang H, Holland-Linn J, Chen DH, Sim BK (2001) Endostatin binds tropomyosin: a potential modulator of the antitumor activity of endostatin. J Biol Chem 276:25190–25196PubMedCrossRef

18.

Dixelius J, Cross Mi, Matsumoto T, Sasaki T, Claseson-Welsh L (2002) Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 62:1944–1947PubMed

19.

Chen YH, Wu HL, Li C, Huang YH, Chiang CW, Wu MP, Wu LW (2006) Anti-angiogenesis mediated by angiostatin K1–3, K1–4 and K1–4.5. Involvement of p53, FasL, AKT and mRNA deregulation. Thromb Haemost 95:668–677PubMed

20.

Gupta N, Nodzenski E, Khodarev NN, Yu J, Khorasani L, Beckett MA, Kufe DW, Weichselbaum RR (2001) Angiostatin effects on endothelial cells mediated by ceramide and RhoA. EMBO Rep 2:536–540PubMed

21.

Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engström A, Timpl R, Welsh M, Claesson-Welsh L (2000) Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95:3403–3411PubMed

22.

Kang HY, Shim D, Kang SS, Chang SI, Kim HY (2006) Protein kinase B inhibits endostatin-induced apoptosis in HUVECs. J Biochem Mol Biol 39:97–104PubMedCrossRef

23.

Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Sukhatme VP (1999) Endostatin induces endothelial cell apoptosis. J Biol Chem 274:11721–11726PubMedCrossRef

24.

Feldman AL, Alexander HR Jr, Bartlett DL, Kranda KC, Miller MS, Costouros NG, Choyke PL, Libutti SK, Feldman AL (2001) A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol 8:741–745PubMedCrossRef

25.

Shaarawy M, EI-Sharkawy SA (2001) Biomarker of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer. Acta Oncol 40:513–518PubMedCrossRef

26.

Feldman AL, Alexander HR Jr, Yang JC, Linehan WM, Eyler RA, Libutti MS (2002) Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 95:1637–1643PubMedCrossRef

27.

Zhao J, Yan F, Ju H, Tang J, Qin J (2004) Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 204:87–95PubMedCrossRef

28.

Bjornland K, Buo L, Scott H, Konttinen Y, Johansen HT, Aasen AO (1998) Polymorphonuclear elastase in human colorectal carcinoma. Int J Oncol 12:535–540PubMed

29.

Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR Jr, Libutti SK (2000) Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 6:4628–4634PubMed

30.

Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG (2002) Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277:27872–27879PubMedCrossRef

31.

Shantha Kumara HMC, Kirman I, Feingold D, Cekic V, Nasar A, Arnell T, Balik E, Hoffman A, Baxter R, Conte S, Whelan RL (2009) Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection. Eur J Surg Oncol 35(3):295–301PubMed

32.

Wu FP, Sietses C, von Blomberg BM, van Leeuwen PA, Meijer S, Cuesta MA (2003) Systemic and peritoneal inflammatory response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. Dis Colon Rectum 46:147–155PubMedCrossRef

Title: Plasma levels of angiostatin and endostatin remain unchanged for the first 3 weeks after colorectal cancer surgery
Authors: H. M. C. Shantha Kumara
Samer T. Tohme
Xiaohong Yan
Abu Nasar
Anthony J. Senagore
Matthew F. Kalady
Neil Hyman
Ik Y. Kim
Richard L. Whelan
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Surgical Endoscopy / Issue 6/2011
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-010-1491-2

At a glance: The STEP trials

Springer Medicine

Plasma levels of angiostatin and endostatin remain unchanged for the first 3 weeks after colorectal cancer surgery

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2011

Panel report: best practices for the surgical treatment of obesity

Outcome of 141 cases of self-expandable metallic stent placements for malignant and benign colorectal strictures in a single center

Laparoscopic repair of congenital bilateral Morgagni hernia

Laparoscopic bile duct exploration seems to be safe in higher-risk patients compared to endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy, in a high-volume centre

Glissonian approach for laparoscopic mesohepatectomy

One-stage laparoscopic bisegmentectomy 7–8 and bisegmentectomy 2–3 for bilateral colorectal liver metastases